Hyperkalemia

Finerenone Gets Priority Review for Diabetic Kidney Disease

Publish Date January 18, 2021

The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.

RAS Continuation Linked With Survival Benefit in Advanced CKD

Publish Date January 12, 2021

However, the new study finds a higher risk of kidney replacement therapy with continuation of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy.

NSAIDs May Increase AKI, Hyperkalemia Risks in Diabetes

Publish Date December 17, 2020

Study findings suggest NSAIDs may be a risk factor for acute kidney injury and hyperkalemia in patients with diabetes.

Potassium Binders’ Efficacy in Infant Formula Probed

Publish Date December 17, 2020

Milk formulas with low potassium content are not readily available or covered by medical insurance.

Potassium Supplementation May Be Feasible in Chronic Kidney Disease

Publish Date December 16, 2020

In a short-term study, patients with stage 3 to 4 CKD received 40 mEq potassium supplements daily for 2 weeks.

Manage Hyperkalemia in CKD by Means Other Than Stopping RAAS Inhibitors

Publish Date December 10, 2020

A “fine balance” in CKD management is needed to prevent mortality, according to investigators.

Hyperkalemia Rates High in Diabetic Kidney Disease

Publish Date November 16, 2020

Investigators observed higher hyperkalemia rates among patients with diabetes with coexisting chronic kidney disease and/or a history of cardiovascular events.

Study: SZC Treatment Does Not Increase Hypokalemia Risk

Publish Date November 16, 2020

Use of sodium zirconium cyclosilicate to treat hyperkalemia does not appear to markedly increase the risk for a drop in serum potassium to less than 3.5 mmol/L.

High Hyperkalemia Recurrence Burden Found After SPS Use

Publish Date November 13, 2020

In a study of inpatients with hyperkalemia, less than 1% of sodium polystyrene sulfonate (SPS) users received SPS upon discharge.

SGLT2 Inhibitors Linked to Hyperkalemia, Electrolyte Abnormalities in CKD

Publish Date November 10, 2020

In a real-world study, a subset of patients initiating canagliflozin, empagliflozin, or dapagliflozin for diabetes experienced new hyperkalemia.